English  |  正體中文  |  简体中文  |  Items with full text/Total items : 62796/95837 (66%)
Visitors : 3640510      Online Users : 390
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library & TKU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/115978


    Title: Sodium Benzoate, a D-amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
    Authors: Chieh-Hsin Lin;Ching-Hua Lin;Yue-Cune Chang;Yu-Jhen Huang;Po-Wei Chen;Hsien-Yuan Lane
    Keywords: Antioxidant;Clinical trial;D-amino acid oxidase (DAAO) inhibitor, N-methyl-D-aspartate;Refractory schizophrenia;Sodium benzoate
    Date: 2018-09-15
    Issue Date: 2019-03-14 12:11:03 (UTC+8)
    Abstract: BACKGROUND: Clozapine is the last-line antipsychotic agent for refractory schizophrenia. To date, there is no
    convincing evidence for augmentation on clozapine. Activation of N-methyl-D-aspartate receptors, including
    inhibition of D-amino acid oxidase that may metabolize D-amino acids, has been reported to be beneficial for
    patients receiving antipsychotics other than clozapine. This study aimed to examine the efficacy and safety of a
    D-amino acid oxidase inhibitor, sodium benzoate, for schizophrenia patients who had poor response to clozapine.
    METHODS: We conducted a randomized, double-blind, placebo-controlled trial. Sixty schizophrenia inpatients that
    had been stabilized with clozapine were allocated into three groups for 6 weeks’ add-on treatment of 1 g/day sodium
    benzoate, 2 g/day sodium benzoate, or placebo. The primary outcome measures were Positive and Negative
    Syndrome Scale (PANSS) total score, Scale for the Assessment of Negative Symptoms, Quality of Life Scale, and
    Global Assessment of Functioning. Side effects and cognitive functions were also measured.
    RESULTS: Both doses of sodium benzoate produced better improvement than placebo in the Scale for the
    Assessment of Negative Symptoms. The 2 g/day sodium benzoate also produced better improvement than placebo
    in PANSS-total score, PANSS-positive score, and Quality of Life Scale. Sodium benzoate was well tolerated without
    evident side effects. The changes of catalase, an antioxidant, were different among the three groups and correlated
    with the improvement of PANSS-total score and PANSS-positive score in the sodium benzoate group.
    CONCLUSIONS: Sodium benzoate adjuvant therapy improved symptomatology of patients with clozapine-resistant
    schizophrenia. Further studies are warranted to elucidate the optimal
    Relation: Biological Psychiatry 84(6), p.422-432
    DOI: 10.1016/j.biopsych.2017.12.006
    Appears in Collections:[數學學系暨研究所] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML138View/Open

    All items in 機構典藏 are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library & TKU Library IR teams. Copyright ©   - Feedback